Matthew D Rousculp
Biographic Data
| ID | 2804411 |
|---|---|
| NAME | Matthew D Rousculp |
| GIVEN NAMES | Matthew D |
| FAMILY NAME | Rousculp |
| SIGNATURE | ROUSCULP M D |
| AFFILIATIONS | Eli Lilly (United States) |
| ORCID | 0009-0001-2509-1098 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2005 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Real-world impact of NVX-CoV2373 Covid-19 vaccine in immunocompromised individuals in South Korea
A similar risk of medically attended SARS-CoV-2 infection between IIC and non-IC was observed with both a homologous primary series and homologous or heterologous third and fourth doses of NVX-CoV2373, as well as across a variety of immunocompromising conditions
Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population
No prominent works on this page.
Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population
Real-world impact of NVX-CoV2373 Covid-19 vaccine in immunocompromised individuals in South Korea
A similar risk of medically attended SARS-CoV-2 infection between IIC and non-IC was observed with both a homologous primary series and homologous or heterologous third and fourth doses of NVX-CoV2373, as well as across a variety of immunocompromising conditions
Biostatistics (1 work) · Bone health and osteoporosis research (1 work) · Breast cancer (1 work) · Cancer (1 work) · Cancer Risks and Factors (1 work) · Cohort (1 work) · Cohort study (1 work) · COVID-19 Clinical Research Studies (1 work) · Demography (1 work) · Demography (1 work)